Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.

Earlier patent litigation can be reformed to reflect similar success across Europe, resulting in accelerated US biosimilar ...

Runner-up finishes at the US Open, Amgen Irish Open and BMW Championship were among 10 ... while he will make an eighth consecutive Ryder Cup appearance for Team Europe later this year at Bethpage ...

Amgen Inc. hasn't fared too well in recent months, as potential regulatory concerns take over. We cover some of the major sub-plots that could dominate the upcoming Q4 earnings event, due to take ...